Edgeline Holdings to Add Industry Veteran to Its Scientific Advisory Board.

HOUSTON -- Edgeline Holdings, Inc. (OTCBB:ELHI), which recently announced a name change to Oncolin Therapeutics, Inc., announced that Dr. Sandra Silberman has agreed to join the Scientific Advisory Board. Dr. Silberman is a world renowned oncologist who has

been involved in both cancer research and the development of important new cancer therapeutics. At Pfizer, she pioneered the early clinical development of Tarceva and went on to be clinical director of the Gleevec program at Novartis. She continues to be involved in the development of novel cancer therapies being developed by Industry.

"It will be a major asset for Edgeline Holdings/Oncolin to have such an experienced and successful clinical strategist," said Dr. Donald Picker, COO of the company.

Recent News

Edgeline Holdings announced that it has agreed to terms for an exclusive worldwide right to option patents covering the composition and use of Genistein analogs for cancer treatment.

Edgeline Holdings announced its research program receives peer reviewed National Institute of Health Grant of $179,000.

Edgeline Holdings recently announced it had obtained an exclusive option agreement with The University of Texas M.D. Anderson Cancer Center which provides the company the right to negotiate a license for five technologies relating to the treatment of various cancers over a nine month period.

Edgeline Holdings recently announced a Joint Development Agreement with Houston Pharmaceuticals, Inc. to assist the company in obtaining a license for certain patents.

About Edgeline Holdings, Inc.

Headquartered in Houston, Texas, Edgeline Holdings, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies.

Safe Harbor Statement

This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Edgeline's future business and financial results, refer to Edgeline's Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Edgeline Holdings undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.